Updated results of the phase I CheckMate-016 trial include findings for the Opdivo (sunitinib) and Yervoy (pazopanib) combinations showed the overall response rate (ORR; secondary endpoint) was 40.4% (n=47) in both arms.
Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.
